Burzynski's Cure and Coley's Lost Cure
The extraordinary documentary on Dr. Stanislow Burzynski has been making the rounds the past few days. Born in Poland, Burzynski now practices medicine in Houston, Texas, where he pioneered cancer therapy with antineoplastons, nontoxic peptides in the human body that prevent cancers. Burzynski discovered that cancer patients were deficient in antineoplastons and has been successfully treating patients with them for two decades. His nontoxic treatment is far more successful that most current toxic chemotherapies and radiation, particularly for patients with brain cancer who haven’t had prior chemo and radiation.
Burzynski versus the government
While Burzynski has recorded phenomenal success treating patients, the FDA has tried to shut him down repeatedly. The agency has taken him to court several times and tried—unsuccessfully —to haul him off to jail, while the National Cancer Institute initiated antineoplaston drug trials using too-low dosages to discredit Burzynski’s discovery, and the government managed to secure patents for antineoplastons, which Burzynski had already secured years earlier.
While Burzynski has recorded phenomenal success treating patients, the FDA has tried to shut him down repeatedly. The agency has taken him to court several times and tried—unsuccessfully —to haul him off to jail, while the National Cancer Institute initiated antineoplaston drug trials using too-low dosages to discredit Burzynski’s discovery, and the government managed to secure patents for antineoplastons, which Burzynski had already secured years earlier.
My mother's cancer
Back in 1995, my mother was suffering from colon cancer. My father, a physician, contacted Burzynski, who said that his treatment didn’t work for colon cancer—at least at that time. So my mother endured the standard chemo—the aptly named 5FU—and died in 1998.
Back in 1995, my mother was suffering from colon cancer. My father, a physician, contacted Burzynski, who said that his treatment didn’t work for colon cancer—at least at that time. So my mother endured the standard chemo—the aptly named 5FU—and died in 1998.
After she died, I started researching chemo drugs like 5FU and realized how useless most standard chemotherapy was for most tumors (the exceptions are testicular cancer, leukemia, lymphoma and Wilms’ tumor). Boy, was I pissed; I realized how duped I had been. (My father knew 5FU wouldn't cure my mother, but what else was there?) Reading cancer studies—not just the abstracts—I learned that most chemo and radiation shrink tumors but don't extend life, and when the tumors grow back, they’re often far more virulent. That certainly was the case with my mother’s cancer.
William Coley
In my research, I came across the pioneering cancer research in the late 1800s of Dr. William Coley, a brilliant, handsome New York doctor at Memorial Hospital, which is now called Memorial Sloan Kettering. His cancer research began in 1890, when Elizabeth Dashiell, a delicate young woman of 17, was diagnosed with bone cancer in her right hand. William Coley, a graduate of Harvard Medical School, was her 28-year-old surgeon. Since her diagnosis had come early in the course of the disease, amputation of her afflicted arm below the elbow was swift. Yet she died a few months later.
In my research, I came across the pioneering cancer research in the late 1800s of Dr. William Coley, a brilliant, handsome New York doctor at Memorial Hospital, which is now called Memorial Sloan Kettering. His cancer research began in 1890, when Elizabeth Dashiell, a delicate young woman of 17, was diagnosed with bone cancer in her right hand. William Coley, a graduate of Harvard Medical School, was her 28-year-old surgeon. Since her diagnosis had come early in the course of the disease, amputation of her afflicted arm below the elbow was swift. Yet she died a few months later.
Distraught over her death, Coley began poring over old patient records—for what, he wasn’t sure. As Coley read the dusty charts, he saw that most cancer therapies failed; most of the patients died. But curiously, one patient who was severely afflicted with sarcoma, a cancer of the connective tissue, did recuperate. Hospitalized and near death in the fall of 1884, he experienced two outbreaks of a severe skin infection called erysipelas. Caused by a strep bacterium, the infections resulted in high fevers and roused his sleepy immune system. The bumpy, plum-sized tumor below his left ear began to shrink and the patient rallied, recovering completely. When the tenacious Coley tracked the man down, he was well with no cancer recurrence some seven years later.
Uncharted territory
Because Coley’s discovery transpired more than a century ago when the immune system was uncharted territory, the scientist didn’t understand how the patient’s strep infection could bring about a cancer remission. Nevertheless, the prescient physician thought perhaps he had stumbled across something important—a novel way to treat cancer—and began a series of experiments, injecting first live strep bacterium and later killed strep, as it was safer, into patients with sarcomas. The first patient he treated recovered completely, many more followed, and the young surgeon soon published his first paper.
Because Coley’s discovery transpired more than a century ago when the immune system was uncharted territory, the scientist didn’t understand how the patient’s strep infection could bring about a cancer remission. Nevertheless, the prescient physician thought perhaps he had stumbled across something important—a novel way to treat cancer—and began a series of experiments, injecting first live strep bacterium and later killed strep, as it was safer, into patients with sarcomas. The first patient he treated recovered completely, many more followed, and the young surgeon soon published his first paper.
But because scientists didn’t understand how the toxins worked, the treatment was never fully embraced. When Coley’s boss at Memorial, Dr. James Ewing—a snappish widower who liked his chicken rare, his lamb overcooked, and his clothes dated and baggy— decided to champion a new cancer treatment—radiation—the fix was in. Radiation soon eclipsed Coley's toxins, Coley and Ewing became fierce rivals, and Coley's discovery was relegated to a footnote in cancer research. In 1965, in what now seems an incredible lapse of judgment, the American Cancer Society consigned Coley’s vaccine to the list of “unproven” cancer drugs, where it joined the crooked ranks of coffee enemas and laetrile. In fact, his toxins were a more effective cancer treatment than most current chemotherapy and radiation.
Book proposal
After reading about this extraordinary man, a century ahead of his time, I decided to write a book about him, with the working title The Genius and the Other Guy. My agent loved the book proposal but not the title, which he changed to The Lost Cure. But the publishing houses didn’t go for it in any event. “Who cares about a failed cancer treatment?” was the common refrain.
After reading about this extraordinary man, a century ahead of his time, I decided to write a book about him, with the working title The Genius and the Other Guy. My agent loved the book proposal but not the title, which he changed to The Lost Cure. But the publishing houses didn’t go for it in any event. “Who cares about a failed cancer treatment?” was the common refrain.
Ah! If only the sheep didn’t dictate what books were sold, what drugs were approved and what scientific discoveries were embraced, we’d all be so much better off, wouldn’t we?
-----------------------------
-----------------------------
This article is copyright CFS Central 2010. All Rights Reserved. You may quote up to 150 words from this article as long as you indicate in the body of your post (as opposed to a footnote or an endnote) that the excerpt is by Mindy Kitei for CFS Central. You may not reprint more than 150 words from this article on blogs, forums, websites or any other online or print venue. Instead, refer readers to this blog to read the article.
Public service announcement: People interested in being treated with the experimental ME/CFS drug Ampligen in the San Francisco Bay area and can afford the circa $2,500 a month that the drug and infusions will cost, please contact: samp511@comcast.net
Public service announcement: People interested in being treated with the experimental ME/CFS drug Ampligen in the San Francisco Bay area and can afford the circa $2,500 a month that the drug and infusions will cost, please contact: samp511@comcast.net
.jpg){kind=small}
